Diagnostics and devices play stronger hand at Chugai Pharmaceutical
This article was originally published in Clinica
Chugai Pharmaceutical (Japan) has reported an 11.3% rise in diagnostics sales in 1994. Turnover in the division reached ¥,900 million ($91 million), says the company, and was led by sales of DNA probes and enzyme-immunoassay diagnostic systems. Chugai launched its DNA probe for tuberculosis diagnosis in May 1994.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.